The researchers have conducted a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique aimed at ...

Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® ...

In this op-ed, Charles Gersbach explores how genetic tuning is emerging as a next-generation approach to modulating gene ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...

About 150 people in Singapore have transthyretin amyloid cardiomyopathy. Read more at straitstimes.com. Read more at ...

The company had also said last month that Paul Stoffels, a pharma legend who took on the CEO role in 2022 in a bid to ...

Cancer care has changed dramatically over the last decade. As opposed to a "one-size-fits-all" approach, treatment today is ...

The country's third most valuable company by market cap is a study in contrasts. It's a wealth-altering 13-bagger over the ...

Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat ...

Crispr-Cas9 is a tool for making precise edits in DNA, discovered in bacteria. The acronym stands for 'Clustered Regularly ...

Babyscripts, the leading virtual maternity care program for managing obstetrics, announced a partnership with Withings Health Solutions, a pioneer in digital health technology, to enhance its remote ...